Trial Profile

A 3-year randomized, open label, multi-centre investigator driven study comparing de novo enteric coated mycophenolate sodium with delayed onset everolimus, both arms in combination with cyclosporin (using C2 monitoring) and corticosteroids for the prevention of bronchiolitis obliterans syndrome in heart-lung, bilateral lung and single lung transplantation.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 01 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ciclosporin (Primary) ; Everolimus (Primary) ; Mycophenolate sodium (Primary) ; Corticosteroids
Indications Bronchiolitis obliterans; Lung transplant rejection
Focus Therapeutic Use
Acronyms CeMyLung

23 Aug 2013 Status changed from recruiting to completed as reported by Australian New Zealand Clinical Trials Registry.
21 Apr 2012 3-year results presented at the 32nd Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation.
30 Apr 2011 Planned number of patients changed from 240 to 320.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com